Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;26(10):603-608.
doi: 10.1007/s11883-024-01231-5. Epub 2024 Aug 16.

Obicetrapib-the Rebirth of CETP Inhibitors?

Bliss Chang  1 , Luke J Laffin  2   3 , Ashish Sarraju  2   3 , Steven E Nissen  4   5
Affiliations
Review

Obicetrapib-the Rebirth of CETP Inhibitors?

Bliss Chang et al. Curr Atheroscler Rep. 2024 Oct.

Abstract

Purpose of review: To provide perspective on the current development status, and potential future role, of obicetrapib, a third-generation cholesterylester transfer protein (CETP) inhibitor. Obicetrapib has received recent attention following positive Phase II clinical trial data and initiation of Phase III trials for the treatment of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).

Recent findings: The ROSE and ROSE2 trials are Phase II studies that examined the lipid lowering effects of obicetrapib in patients on pre-existing high-intensity statin therapy. Obicetrapib significantly reduced key dyslipidemia biomarkers including low density lipoprotein cholesterol (LDL-C), Apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) while increasing high-density lipoprotein cholesterol (HDL-C). Four phase III clinical trials, including a cardiovascular outcomes trial, are ongoing. Preliminary data for obicetrapib shows favorable effects on dyslipidemia, which could theoretically lead to a decrease in ASCVD clinical events. Short-term safety data in preliminary studies shows no significant safety signals.

Keywords: CETP; Cholesterylester transfer protein inhibitor; Lipid lowering; Low-density lipoprotein; Obicetrapib.

PubMed Disclaimer

Conflict of interest statement

Chang – No disclosures.

Laffin – Dr. Laffin is a consultant and/or served on steering committees for Medtronic, Lilly, Mineralys Therapeutics, AstraZeneca, Idorsia, New Amsterdam, and Crispr Therapeutics; has received research funding from AstraZeneca; and has ownership interest in LucidAct Health and Gordy Health.

Sarraju – Dr. Sarraju is the principal investigator of the TANDEM trial of obicetrapib. He receives no personal renumeration for this role as it paid to the C5 Research, the academic research organization of the Cleveland Clinic’s Heart, Vascular, and Thoracic Institute.

Nissen – Dr. Nissen is the study chair for the TANDEM trial and a member of the Executive Committee supervising the PREVAIL Trial.

Figures

Fig. 1
Fig. 1
Changes in Key Lipid Markers in Phase II Obicetrapib Trials [22, 24]
See this image and copyright information in PMC

References

    1. Mortality in the United States: past, present, and future. In: Budget model. University of Pennsylvania. 2016. https://www.budgetmodel.wharton.upenn.edu/issues/2016/1/25/mortality-in-.... Accessed 4 July 2024.
    1. World Health Organization. In: Leading causes of death globally. 2020. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 4 July 2024.
    1. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–80. 10.1001/jama.291.9.1071. 10.1001/jama.291.9.1071 - DOI - PubMed
    1. Sarraju A, Nissen SE. Atherosclerotic plaque stabilization and regression: a review of clinical evidence. Nat Rev Cardiol. 2024;21:487–97. 10.1038/s41569-023-00979-8. 10.1038/s41569-023-00979-8 - DOI - PubMed
    1. Nelson AJ, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2020;79(18):1802–13. 10.1016/j.jacc.2022.02.048.10.1016/j.jacc.2022.02.048 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources